目的:比较替吉奥单药与吉西他滨单药一线治疗老年人晚期胰腺癌的近期疗效、无进展生存和安全性。方法:回顾性分析我院自2009年1月-2014年8月收治的老年晚期胰腺癌患者44例,一线采用替吉奥单药或吉西他滨单药化疗。替吉奥组21例,吉西他滨...目的:比较替吉奥单药与吉西他滨单药一线治疗老年人晚期胰腺癌的近期疗效、无进展生存和安全性。方法:回顾性分析我院自2009年1月-2014年8月收治的老年晚期胰腺癌患者44例,一线采用替吉奥单药或吉西他滨单药化疗。替吉奥组21例,吉西他滨组23例。每例患者至少接受化疗2个周期以上。每2个周期复查CT,根据实体瘤疗效评价标准(Response Evaluation Criteria In Solid Tu m o r s,R ECI ST)和美国国家癌症研究所化疗毒性分级标准(Nat i o n a l Ca n c e r In s t i t u te Co m m o n Te r m i n o l o g y C r i t e r i a Fo r A d v e r s e Ev e n t s,N C I-C TC A E)对两组治疗的近期疗效、无进展生存(progression-f ree sur v ival,PFS)和不良反应进行评估。结果:44例老年晚期胰腺癌患者经替吉奥或吉西他滨单药化疗,两组的有效率(objective response rate,ORR)及疾病控制率(disease control rate,D CR)相似,差异无统计学意义(P>0.05)。替吉奥组中位PFS3.6月,吉西他滨组中位PFS4.0月,差异无统计学意义(P>0.05)。替吉奥组的骨髓抑制情况明显低于吉西他滨组,其中中性粒细胞减少差异有统计学意义(P=0.01)。其它的药物相关不良反应主要为1-2级胃肠道反应和肝功能异常。结论:替吉奥单药对比吉西他滨单药一线治疗老年晚期胰腺癌,两组疗效相似,但替吉奥的化疗毒性反应明显较小,患者能耐受,口服给药方便,可推荐作为老年晚期胰腺癌的一线化疗方案,尤其可能适用于PS评分2分的不能耐受吉西他滨或其他联合方案的老年晚期胰腺癌患者。展开更多
目的:探究富含亮氨酸重复序列蛋白1(leucine-rich repeat protein 1,LRR1)在乳腺癌细胞中的表达及对其生物学功能的影响。方法:培养人乳腺癌MDA-MB-231、HCC70细胞株和正常乳腺上皮MCF-10A细胞;采用蛋白免疫印迹法检测LRR1表达。将人乳...目的:探究富含亮氨酸重复序列蛋白1(leucine-rich repeat protein 1,LRR1)在乳腺癌细胞中的表达及对其生物学功能的影响。方法:培养人乳腺癌MDA-MB-231、HCC70细胞株和正常乳腺上皮MCF-10A细胞;采用蛋白免疫印迹法检测LRR1表达。将人乳腺癌MDA-MB-231、HCC70细胞株分为干扰对照组、LRR1干扰组、LRR1过表达组和空载体对照组,分别转染LRR1对照、干扰、过表达、空载体序列;采用Transwell实验检测乳腺癌细胞迁移和侵袭能力;采用蛋白免疫印迹法检测细胞中哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,m-TOR)表达。结果:与正常人乳腺上皮MCF-10A细胞相比,乳腺癌MDA-MB-231和HCC70细胞中LRR1表达水平显著增加(P均<0.01)。在人乳腺癌MDA-MB-231、HCC70细胞中,与干扰对照组相比,LRR1干扰组细胞迁移和侵袭数显著降低(P均<0.01),m-TOR表达水平明显降低(P<0.01);与空载体对照组相比,过表达LRR1组细胞迁移和侵袭数显著增加(P均<0.01),m-TOR蛋白表达水平明显增加(P均<0.01)。结论:LRR1在乳腺癌细胞中呈高表达,并可促进其迁移和侵袭。展开更多
This meta-analysis was carried out to evaluate the relationship between NM23 expression and the prognosis of patients with colorectal cancer. We searched Pub Med, EMBASE and Web of Science for relevant articles. The p...This meta-analysis was carried out to evaluate the relationship between NM23 expression and the prognosis of patients with colorectal cancer. We searched Pub Med, EMBASE and Web of Science for relevant articles. The pooled odd ratios（ORs） and corresponding 95%CI were calculated to evaluate the prognostic value of NM23 expression in patients with colorectal cancer, and the association between NM23 expression and clinicopathological factors. In total, 2289 patients were pooled from 24 available studies. The incorporative OR combined by 16 studies with overall survival showed that high NM23 expression was associated with better overall survival（OR=0.67, 95%CI： 0.49–0.93, P=0.02, I2=56%, Ph=0.004）. And a new estimate without heterogeneity was produced when only combining high-quality studies（OR=0.70, 95%CI： 0.56–0.86, P=0.0007, I2=46%）. In disease free survival（DFS）, we also obtained a good prognosis（OR=0.30, 95%CI： 0.14–0.68, P=0.004）. Although we failed to find any significance in N status（P=0.10）, elevated NM23 expression was related to well tumor differentiation（OR=0.60, 95%CI： 0.44–0.820, P=0.001） and Dukes＇ A＆B（OR=0.55, 95%CI： 0.32–0.95, P=0.03）. These results indicated that over-expressed NM23 might be an indicator of good prognosis, well tumor differentiation and Dukes＇ A＆B of patients with colorectal cancer, but no significance was found in N status.展开更多
文摘目的:比较替吉奥单药与吉西他滨单药一线治疗老年人晚期胰腺癌的近期疗效、无进展生存和安全性。方法:回顾性分析我院自2009年1月-2014年8月收治的老年晚期胰腺癌患者44例,一线采用替吉奥单药或吉西他滨单药化疗。替吉奥组21例,吉西他滨组23例。每例患者至少接受化疗2个周期以上。每2个周期复查CT,根据实体瘤疗效评价标准(Response Evaluation Criteria In Solid Tu m o r s,R ECI ST)和美国国家癌症研究所化疗毒性分级标准(Nat i o n a l Ca n c e r In s t i t u te Co m m o n Te r m i n o l o g y C r i t e r i a Fo r A d v e r s e Ev e n t s,N C I-C TC A E)对两组治疗的近期疗效、无进展生存(progression-f ree sur v ival,PFS)和不良反应进行评估。结果:44例老年晚期胰腺癌患者经替吉奥或吉西他滨单药化疗,两组的有效率(objective response rate,ORR)及疾病控制率(disease control rate,D CR)相似,差异无统计学意义(P>0.05)。替吉奥组中位PFS3.6月,吉西他滨组中位PFS4.0月,差异无统计学意义(P>0.05)。替吉奥组的骨髓抑制情况明显低于吉西他滨组,其中中性粒细胞减少差异有统计学意义(P=0.01)。其它的药物相关不良反应主要为1-2级胃肠道反应和肝功能异常。结论:替吉奥单药对比吉西他滨单药一线治疗老年晚期胰腺癌,两组疗效相似,但替吉奥的化疗毒性反应明显较小,患者能耐受,口服给药方便,可推荐作为老年晚期胰腺癌的一线化疗方案,尤其可能适用于PS评分2分的不能耐受吉西他滨或其他联合方案的老年晚期胰腺癌患者。
文摘目的:探究富含亮氨酸重复序列蛋白1(leucine-rich repeat protein 1,LRR1)在乳腺癌细胞中的表达及对其生物学功能的影响。方法:培养人乳腺癌MDA-MB-231、HCC70细胞株和正常乳腺上皮MCF-10A细胞;采用蛋白免疫印迹法检测LRR1表达。将人乳腺癌MDA-MB-231、HCC70细胞株分为干扰对照组、LRR1干扰组、LRR1过表达组和空载体对照组,分别转染LRR1对照、干扰、过表达、空载体序列;采用Transwell实验检测乳腺癌细胞迁移和侵袭能力;采用蛋白免疫印迹法检测细胞中哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,m-TOR)表达。结果:与正常人乳腺上皮MCF-10A细胞相比,乳腺癌MDA-MB-231和HCC70细胞中LRR1表达水平显著增加(P均<0.01)。在人乳腺癌MDA-MB-231、HCC70细胞中,与干扰对照组相比,LRR1干扰组细胞迁移和侵袭数显著降低(P均<0.01),m-TOR表达水平明显降低(P<0.01);与空载体对照组相比,过表达LRR1组细胞迁移和侵袭数显著增加(P均<0.01),m-TOR蛋白表达水平明显增加(P均<0.01)。结论:LRR1在乳腺癌细胞中呈高表达,并可促进其迁移和侵袭。
文摘This meta-analysis was carried out to evaluate the relationship between NM23 expression and the prognosis of patients with colorectal cancer. We searched Pub Med, EMBASE and Web of Science for relevant articles. The pooled odd ratios（ORs） and corresponding 95%CI were calculated to evaluate the prognostic value of NM23 expression in patients with colorectal cancer, and the association between NM23 expression and clinicopathological factors. In total, 2289 patients were pooled from 24 available studies. The incorporative OR combined by 16 studies with overall survival showed that high NM23 expression was associated with better overall survival（OR=0.67, 95%CI： 0.49–0.93, P=0.02, I2=56%, Ph=0.004）. And a new estimate without heterogeneity was produced when only combining high-quality studies（OR=0.70, 95%CI： 0.56–0.86, P=0.0007, I2=46%）. In disease free survival（DFS）, we also obtained a good prognosis（OR=0.30, 95%CI： 0.14–0.68, P=0.004）. Although we failed to find any significance in N status（P=0.10）, elevated NM23 expression was related to well tumor differentiation（OR=0.60, 95%CI： 0.44–0.820, P=0.001） and Dukes＇ A＆B（OR=0.55, 95%CI： 0.32–0.95, P=0.03）. These results indicated that over-expressed NM23 might be an indicator of good prognosis, well tumor differentiation and Dukes＇ A＆B of patients with colorectal cancer, but no significance was found in N status.
